Trials / Completed
CompletedNCT00683865
Uncomplicated Pelvic Inflammatory Disease. Treatment With Moxifloxacin.
Prospective, Randomized, Double-blind, Multicenter, Multinational Study Comparing Efficacy and Safety of Moxifloxacin 400 mg po od for 14 Days With Ofloxacin 400 mg po Bid Plus Metronidazole 500 mg po Bid for 14 Days in Patients With Uncomplicated Pelvic Inflammatory Disease (PID)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 749 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Comparison of various antibiotics in treatment of uncomplicated pelvic inflammatory disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ofloxacin | Ofloxacin 400 mg po bid plus metronidazole 500 mg po bid for 14 days |
| DRUG | Avelox (Moxifloxacin, BAY12-8039) | Moxifloxacin 400 mg po od for 14 days |
Timeline
- Start date
- 2003-04-01
- Primary completion
- 2004-10-01
- Completion
- 2004-10-01
- First posted
- 2008-05-26
- Last updated
- 2014-10-15
Locations
77 sites across 13 countries: Denmark, Finland, France, Germany, Greece, Hungary, Italy, Lithuania, Poland, Russia, South Africa, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00683865. Inclusion in this directory is not an endorsement.